Atrial Fibrillation - Pipeline Review, H1 2018

  • ID: 4464774
  • Drug Pipelines
  • 98 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acesion Pharma Aps
  • ARCA biopharma Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Cardiome Pharma Corp
  • Daiichi Sankyo Co Ltd
  • MORE
Atrial Fibrillation - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H1 2018, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 4, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acesion Pharma Aps
  • ARCA biopharma Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Cardiome Pharma Corp
  • Daiichi Sankyo Co Ltd
  • MORE
Introduction

The Publisher's Report Coverage

Atrial Fibrillation - Overview

Atrial Fibrillation - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Atrial Fibrillation - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Atrial Fibrillation - Companies Involved in Therapeutics Development

Acesion Pharma Aps

ARCA biopharma Inc

AstraZeneca Plc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Cardiome Pharma Corp

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

Edge Therapeutics Inc

Gilead Sciences Inc

InCarda Therapeutics Inc

Merck & Co Inc

N-Gene Research Laboratories Inc

Nissan Chemical Industries Ltd

OMEICOS Therapeutics GmbH

The Geneva Biotech Center SA

Verseon Corp

Atrial Fibrillation - Drug Profiles

AFC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGP-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-919373 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-1728515 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bucindolol hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budiodarone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edoxaban tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-1965 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flecainide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBCA-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Atrial Fibrillation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-967 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heparin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-1832 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NIP-151 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Calcium Activated Potassium Channel for Atrial Fibrillation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LGALS3 for Cardiovascular, Respiratory and Genito Urinary System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-1902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-2851 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vernakalant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Atrial Fibrillation - Dormant Projects

Atrial Fibrillation - Discontinued Products

Atrial Fibrillation - Product Development Milestones

Featured News & Press Releases

Dec 12, 2017: Espero BioPharma Provides Update on Budiodarone

Nov 15, 2017: New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017

Nov 13, 2017: OMEICOS Announces Formation of Inaugural Clinical Advisory Board

Nov 08, 2017: Daiichi Sankyo Announces New Analyses of Once-Daily SAVAYSA (edoxaban) to be Presented at the 2017 American Heart Association Scientific Sessions

Nov 02, 2017: Cardiome Announces Expansion of Global Geographic Footprint for Brinavess

Oct 06, 2017: Daiichi Sankyo to Install Call Center Support System in Japan Utilizing Artificial Intelligence

Sep 14, 2017: G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals

Aug 30, 2017: New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS

Aug 29, 2017: New Sub-analysis Data Highlights the Benefit of LIXIANA (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring

Aug 21, 2017: Daiichi Sankyo Announces Its Clinical Presentations at ESC Congress 2017

Aug 21, 2017: Cardiome Provides U.S. Regulatory Update For BRINAVESS

Jul 17, 2017: CHMP Issues a Positive Opinion for Daiichi Sankyos Once-Daily LIXIANA (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion

Jun 12, 2017: Cardiome Announces Commercial Launch of BRINAVESS (Vernakalant Hydrochloride) in Canada

Jun 07, 2017: InCarda Therapeutics Announces Positive Clinical Data Supporting Development of Inhaled Flecainide for the Treatment of Symptomatic Acute Events of Paroxysmal Atrial Fibrillation

Jun 07, 2017: OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Atrial Fibrillation, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H1 2018

Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H1 2018

Atrial Fibrillation - Pipeline by AstraZeneca Plc, H1 2018

Atrial Fibrillation - Pipeline by Boston Pharmaceuticals Inc, H1 2018

Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Co, H1 2018

Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H1 2018

Atrial Fibrillation - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018

Atrial Fibrillation - Pipeline by Edge Therapeutics Inc, H1 2018

Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H1 2018

Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H1 2018

Atrial Fibrillation - Pipeline by Merck & Co Inc, H1 2018

Atrial Fibrillation - Pipeline by N-Gene Research Laboratories Inc, H1 2018

Atrial Fibrillation - Pipeline by Nissan Chemical Industries Ltd, H1 2018

Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H1 2018

Atrial Fibrillation - Pipeline by The Geneva Biotech Center SA, H1 2018

Atrial Fibrillation - Pipeline by Verseon Corp, H1 2018

Atrial Fibrillation - Dormant Projects, H1 2018

Atrial Fibrillation - Dormant Projects, H1 2018 (Contd..1), H1 2018

Atrial Fibrillation - Dormant Projects, H1 2018 (Contd..2), H1 2018

Atrial Fibrillation - Discontinued Products, H1 2018

Atrial Fibrillation - Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

Number of Products under Development for Atrial Fibrillation, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acesion Pharma Aps
  • ARCA biopharma Inc
  • AstraZeneca Plc
  • Boston Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Cardiome Pharma Corp
  • Daiichi Sankyo Co Ltd
  • Dong-A Socio Holdings Co Ltd
  • Edge Therapeutics Inc
  • Gilead Sciences Inc
  • InCa
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll